ABOUT THE RESEARCHER

OVERVIEW

The goal of Sandra Burchett's research is to prevent transmission of viruses from mothers to babies. She chairs the committee in the Pediatric AIDS Clinical Trials group that develops studies to understand the safety and usefulness of drugs used to treat HIV and to prevent perinatal transmission of HIV. She also chairs a national protocol for the study of how best to treat children with advanced HIV infection, which focuses on the central nervous system reservoir. 

She has collaborated with Dana Gabuzda at the Dana Farber Cancer Institute to understand more of the pathogenesis of central nervous system HIV infection in children with Dr. Judith Lieberman of the Center for Blood Research in studies of ex vivo immune reconstitution after IL-2 stimulation in persons with HIV infection. Most recently, she has collaborated with Dr. Phillip Goulder at the Massachusetts General Hospital in understanding the host and viral characteristics of HIV-infected children with long-term non-progressive disease.

Dr. Burchett is the site principal investigator for the Boston Pediatric AIDS Clinical Trials Unit. 

She also participates in the longitudinal study (Women and Infant's Transmission Study) of pregnant women and their children with HIV infection and continues to participate in antiviral and antifungal trials of new agents for the immunocompromised population. 

BACKGROUND

Sandra Burchett received her MS from the University of Arkansas and her MD from the University of Arkansas College of Medicine. She completed an internship and residency from Arkansas Children's Hospital and a fellowship at University of Washington Medical Center.

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Rates of Hospitalization and Infection-Related Hospitalization Among Human Immunodeficiency Virus (HIV)-Exposed Uninfected Children Compared to HIV-Unexposed Uninfected Children in the United States, 2007-2016. Clin Infect Dis. 2020 Jul 11; 71(2):332-339. View abstract
  2. Neurodevelopment of HIV-Exposed Uninfected Infants Born to Women With Perinatally Acquired HIV in the United States. J Acquir Immune Defic Syndr. 2020 06 01; 84(2):213-219. View abstract
  3. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy. Antimicrob Agents Chemother. 2020 03 24; 64(4). View abstract
  4. Immune imbalance and activation are associated with lower lung function in youth with perinatally acquired HIV. J Allergy Clin Immunol. 2020 05; 145(5):1473-1476. View abstract
  5. Birth Prevalence of Congenital Cytomegalovirus Infection in HIV-Exposed Uninfected Children in the Era of Combination Antiretroviral Therapy. J Pediatr. 2020 01; 216:82-87.e2. View abstract
  6. Disparities in HIV Viral Suppression Among Adolescents and Young Adults by Perinatal Infection. Am J Public Health. 2019 07; 109(7):e9. View abstract
  7. Immunologic reconstitution following hematopoietic stem cell transplantation despite lymph node paucity in NF-?B-inducing kinase deficiency. J Allergy Clin Immunol. 2019 03; 143(3):1240-1243.e4. View abstract
  8. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018 11 13; 32(17):2507-2516. View abstract
  9. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018 03 27; 32(6):729-737. View abstract
  10. Birth Weight and Preterm Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT P1025 Protocol. Clin Infect Dis. 2017 Sep 15; 65(6):982-989. View abstract
  11. Septic Episodes in a Premature Infant After In Utero Exposure to Rituximab. Pediatrics. 2017 Sep; 140(3). View abstract
  12. Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth. JAMA Pediatr. 2017 05 01; 171(5):450-460. View abstract
  13. Lymphocyte subsets in HIV-exposed uninfected infants and HIV-unexposed uninfected infants. J Allergy Clin Immunol. 2017 08; 140(2):605-608.e3. View abstract
  14. Case Report of a Child after Hematopoietic Cell Transplantation with Acute Aspergillus Tracheobronchitis as a Cause for Respiratory Failure. Case Rep Pediatr. 2016; 2016:9676234. View abstract
  15. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. . 2016 07 01; 72(3):289-96. View abstract
  16. Phenotypic Coreceptor Tropism in Perinatally HIV-infected Youth Failing Antiretroviral Therapy. Pediatr Infect Dis J. 2016 07; 35(7):777-81. View abstract
  17. Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV. Clin Infect Dis. 2016 07 01; 63(1):133-137. View abstract
  18. Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy. J Med Virol. 2016 Jun; 88(6):1051-8. View abstract
  19. Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection. Clin Infect Dis. 2016 Jan 01; 62(1):106-114. View abstract
  20. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. . 2015 Sep 01; 70(1):33-41. View abstract
  21. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. Clin Infect Dis. 2015 Nov 15; 61(10):1582-9. View abstract
  22. Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection. Clin Infect Dis. 2015 Sep 15; 61(6):988-95. View abstract
  23. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015 Sep; 16(8):502-11. View abstract
  24. Effect of cytomegalovirus co-infection on normalization of selected T-cell subsets in children with perinatally acquired HIV infection treated with combination antiretroviral therapy. PLoS One. 2015; 10(3):e0120474. View abstract
  25. Raltegravir pharmacokinetics during pregnancy. . 2014 Dec 01; 67(4):375-81. View abstract
  26. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr. 2014 Dec; 168(12):1138-46. View abstract
  27. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med. 2015 Mar; 16(3):176-83. View abstract
  28. Progressive multifocal leukoencephalopathy in pediatric patients: case report and literature review. Pediatr Infect Dis J. 2014 Apr; 33(4):e99-105. View abstract
  29. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jun; 19(7):1441-9. View abstract
  30. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. . 2013 May 01; 63(1):59-66. View abstract
  31. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant. 2013 Mar; 17(2):133-43. View abstract
  32. Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis. 2012 Aug 01; 206(3):421-30. View abstract
  33. T-cell activation and neurodevelopmental outcomes in perinatally HIV-infected children. AIDS. 2012 May 15; 26(8):959-69. View abstract
  34. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med. 2012 May; 13(5):264-75. View abstract
  35. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 2012 Apr; 13(4):226-35. View abstract
  36. Maternal cytomegalovirus-specific immune responses and symptomatic postnatal cytomegalovirus transmission in very low-birth-weight preterm infants. J Infect Dis. 2011 Dec 01; 204(11):1672-82. View abstract
  37. CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption. . 2011 Jul 01; 57(3):223-9. View abstract
  38. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. . 2011 Jun 01; 57(2):165-73. View abstract
  39. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. . 2011 Apr 15; 56(5):412-9. View abstract
  40. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis. 2011 Apr 15; 52(8):1003-9. View abstract
  41. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. . 2010 Aug; 54(4):381-8. View abstract
  42. CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. . 2010 Jul; 54(3):285-9. View abstract
  43. Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants. . 2010 Jan; 53(1):154-7. View abstract
  44. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010 Apr; 11(4):232-8. View abstract
  45. CYP2C19 Genetic Variants Affect Nelfinavir Pharmacokinetics and Virologic Response in HIV-1-Infected Children Receiving Highly Active Antiretroviral Therapy. . J Acquir Immune Defic Syndr. . 2009. View abstract
  46. Case 15-2009: a man with coma after cardiac arrest. N Engl J Med. 2009 Aug 13; 361(7):725; author reply 725. View abstract
  47. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009 Feb; 104(2):444-53. View abstract
  48. Lopinavir exposure with an increased dose during pregnancy. . 2008 Dec 15; 49(5):485-91. View abstract
  49. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008 Nov; 9(10):875-82. View abstract
  50. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008 Apr; 9(4):214-20. View abstract
  51. High-dose Lopinavir and Standard-dose Emtricitabine Pharmacokinetics during Pregnancy and Postpartum. 15th Conference on Retroviruses and Opportunistic Infections. 2008; 629. View abstract
  52. CYP2C19 Genetic Variants Affect Nelfinavir and M8 Pharmacokinetics and Virologic Response in HIV-1 Infected Children Receiving HAART. 15th Conference on Retroviruses and Opportunistic Infections. 2008; 572. View abstract
  53. Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort. HIV Med. 2007 Nov; 8(8):561-7. View abstract
  54. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007 Oct 18; 21(16):2191-9. View abstract
  55. Viral Infections. Manual of Neonatal Care, Cloherty, Eichenwald, Stark, eds. 2007. View abstract
  56. International perspectives, progress, and future challenges of paediatric HIV infection. Lancet. 2007 Jul 07; 370(9581):68-80. View abstract
  57. Nelfinavir Pharmacokinetics (625-mg Tablets) during the Third Trimester of Pregnancy and Post-partum. 14th Conference on Retroviruses and Opportunistic Infections. 2007; 740. View abstract
  58. Tenofovir Pharmacokinetics during Pregnancy, at Delivery and Postpartum. 14th Conference on Retroviruses and Opportunistic Infections. 2007; 738b. View abstract
  59. Reduced lopinavir exposure during pregnancy. AIDS. 2006 Oct 03; 20(15):1931-9. View abstract
  60. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006 Feb 28; 20(4):553-60. View abstract
  61. Lopinavir exposure with a higher dose during the 3rd trimester of pregnancy. 13th Conference on Retroviruses and Opportunistic Infections. 2006. View abstract
  62. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J of Infec Disease. 2005; 192(2):296-302. View abstract
  63. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol. 2005 Jun 15; 174(12):7524-30. View abstract
  64. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J Infect Dis. 2005 Jul 15; 192(2):296-302. View abstract
  65. Pediatric Human Immunodeficiency Virus Infection. Principles and Practice of Infectious Diseases, Mandell G, Bennett J, Dolin R, eds. 2005; 1638-54. View abstract
  66. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: pediatric AIDS clinical trials group protocol 332. Journal of Infectious Diseases . 2004; 190(12):2167-74. View abstract
  67. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis. 2004 Dec 15; 190(12):2167-74. View abstract
  68. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. International AIDS Conference. 2004; Bangkok. View abstract
  69. Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004 Jul 01; 39(1):107-14. View abstract
  70. Mother-to child HIV transmission risk according to antiretroviral therapy, mode of delivery, and viral load in 2895 US women (PACTG 367). 11th Conference on Retroviruses and Opportunistic Infections. 2004; San Francisco:A99. View abstract
  71. Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clinical Infectious Diseases . 2004; 39(1):107-14. View abstract
  72. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003 Dec 20; 362(9401):2045-51. View abstract
  73. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection. J Immunol. 2003 Dec 15; 171(12):6968-75. View abstract
  74. HIV Infection in Infants, Children, and Adolescents. Pediatrics in Review. 2003; 24:186-93. View abstract
  75. Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children. J Virol. 2003 Jul; 77(13):7492-501. View abstract
  76. HIV infection in infants, children, and adolescents. Pediatr Rev. 2003 Jun; 24(6):186-94. View abstract
  77. Congenital Infections. Manual of Pediatric Practice, Finberg L, editor. 2003. View abstract
  78. Viral Infections. Manual of Neonatal Care, Cloherty JP and Stark AR, editors. 2003; 255-86. View abstract
  79. Pharmakokinetics and Safety of d4T and 3TC in HIV-infected Pregnant Women and Their Infants (PACTG 332). 10th Conference on Retroviruses and Opportunistic Infections. 2003; Boston:A886. View abstract
  80. Robust Gag-specific T-helper Response Associated with Viral Control in Pediatric HIV Infection. 10th Conference on Retroviruses and Opportunistic Infections. 2003; Boston:A299. View abstract
  81. HIV Infection in Infants, Children, and Adolescents. Pediatrics in Review. 2003; 24:186-194. View abstract
  82. Perinatal Infections. Saunders Manual of Pediatric Practice, Finberg L. and Kleinman RE, editors. 2002; 356-61. View abstract
  83. Mother-to-Child HIV Transmission Rates According to Antiretroviral Therapy, Mode of Delivery and Viral Load (PACTG 367). 9th Conference on Retroviruses and Opportunistic Infections. 2002; Seattle:A114. View abstract
  84. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Health Services/Technology Assessment Text. 2001. View abstract
  85. Mother-to-child transmission of HIV infection and CTL escape through HLA-A2-SLYNTVATL epitope sequence variation. Immunol Lett. 2001 Nov 01; 79(1-2):109-16. View abstract
  86. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis. 2001 Nov 15; 184(10):1331-5. View abstract
  87. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature. 2001 Jul 19; 412(6844):334-8. View abstract
  88. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics. 2001 May; 107(5):E77. View abstract
  89. HIV-1 Reverse Transcriptase M184V/I Improves the Rate of Suppression of Viral Replication by Salvage Therapy. 8th Conference on Retroviruses and Opportunistic Infections. 2001; Chicago:A463. View abstract
  90. Virologic and Immunologic Responses in Children with Advanced HIV Disease on a New HAART Regimen (PACTG 366). 8th Conference on Retroviruses and Opportunistic Infections. 2001; Chicago:A684. View abstract
  91. HIV-Infected Children on HAART Reconstitute Tetanus-Specific T Cell Responses without Booster Vaccination. 8th Conference on Retroviruses and Opportunistic Infections. 2001; Chicago:A688. View abstract
  92. Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. Br Med Bull. 2001; 58:89-108. View abstract
  93. Human immunodeficiency virus type 1 (HIV-1) gp 120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. Journal Infectious Diseases. 2001; 184:1331-5. View abstract
  94. Paediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. British Medical Bulletin . 2001; 58:89-108. View abstract
  95. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics . 2001; 107:E77. View abstract
  96. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. International Journal of STD and AIDS . 2001; 12:767. View abstract
  97. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med. 2000 Dec 18; 192(12):1819-32. View abstract
  98. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group. J Infect Dis. 2000 Dec; 182(6):1616-24. View abstract
  99. Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. J Infect Dis. 2000 Nov; 182(5):1385-93. View abstract
  100. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J Virol. 2000 Jun; 74(12):5679-90. View abstract
  101. Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials Group. Antimicrob Agents Chemother. 2000 Apr; 44(4):1041-6. View abstract
  102. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis. 2000 Mar; 181(3):890-6. View abstract
  103. Viral load reduction (VLR) in children with advanced HIV disease treated with 4-drug antiretroviral treatment (ART) regimens including NRTIs, Nevirapine (NVP), Nelfinavir (NFV), and/or Ritonavir (RTV):PACTG 366. 7th Conference on Retroviruses and Opportunistic Infections. 2000; San Francisco:A698. View abstract
  104. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J Infect Dis. 2000 Feb; 181(2):548-54. View abstract
  105. Antepartum antiretroviral therapy and viral load in 464 HIV-infected women in 1998-1999 (PACTG 367). American Journal of Obstetrics and Gynecology. 2000; 182:S99. View abstract
  106. Identification of dominant optimal HLA-B6-and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay. Journal Virology. 2000; 74:8541-9. View abstract
  107. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type-1 infected children (Pediatric AIDS clinical trials group protocol 273). Journal Infectious Diseases. 2000; 181:548-54. View abstract
  108. Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The pediatrics AIDS clinical trials group. Antimicrobial Agents Chemotherapy. 2000; 44:1041-6. View abstract
  109. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The pediatric AIDS clinical trials group. Journal Infectious Dissease . 2000; 182:1616-24. View abstract
  110. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. Journal Acquired Immunodeficiency Syndrome . 2000; 25:261-8. View abstract
  111. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. Journal Experimental Medicine . 2000; 192:1819-32. View abstract
  112. HIV vertical transmission rates according to antiretro-viral therapy and viral load during pregnancy among 347 mother-child pairs 1998-99 (PACTG 367). American Journal of Obstetrics and Gynecology. 2000; 182:S97. View abstract
  113. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999 Aug 05; 341(6):394-402. View abstract
  114. Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. Antimicrob Agents Chemother. 1999 Jun; 43(6):1516-9. View abstract
  115. Preliminary toxicity and tolerability of 4-drug antiretroviral (ARV) therapy with NRTIs, Nevirapine (NVP), Nelfinavir (NFV) and Ritonavir (RTN) in ARV-experienced children with advanced HIV disease. 6th Conference on Retroviruses and Opportunistic Infections. 1999; Chicago. View abstract
  116. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol. 1999 Jan; 73(1):362-7. View abstract
  117. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. Journal of Virology . 1999; 73:362-7. View abstract
  118. Diagnosis of HIV Infection and Markers of Disease Progression in Infants. Pediatric AIDS, Pizzo P and Wilfert C, editors. 1998; 67-87. View abstract
  119. Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. J Neuroimmunol. 1998 Nov 02; 91(1-2):19-27. View abstract
  120. Viral Infections. Manual of Neonatal Care, Cloherty JP and Stark AR, editors. 1998; 239-71. View abstract
  121. Congenital Infections. Saunders Manual of Pediatric Practice, Finberg L, editor. 1998; 299-302. View abstract
  122. Combinations of Didanosine (DDI), Zidovudine (ZDV) and Nevirapine (NVP) can reduce CSF HIV-1 viral load in pediatric patients with advanced HIV disease. 12th World AIDS Conference. 1998; Geneva. View abstract
  123. Maternal human immunodeficiency virus (HIV) RNA level correlates with the risk but does not predict the timing of perinatal transmission. American Journal of Obstetrics and Gynecology. 1998; 178:2S. View abstract
  124. Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. Am J Obstet Gynecol. 1997 Aug; 177(2):450-4. View abstract
  125. Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children. J Pediatr. 1997 Jun; 130(6):898-905. View abstract
  126. Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis. 1997 Apr; 175(4):971-4. View abstract
  127. Lack of detection of human immunodeficiency virus type 1 in the saliva of infected children and adolescents. Arch Pediatr Adolesc Med. 1997 Mar; 151(3):228-32. View abstract
  128. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 01; 14(3):232-6. View abstract
  129. Virologic activity of Didanosine (DDI), Zidovudine (ZDV) and Nevirapine (NVP) combinations in pediatric subjects with advanced HIV disease (ACTG 245). 5th Conferemce on Retroviruses and Opportunistic Infections. 1997; Chicago(Abst 271):A998. View abstract
  130. Effect of pregnancy and zidovudine therapy on viral load in HIV-I-infected women. Journal Acquired Immune Deficiency Syndrome Human Retrovirology. 1997; 14:232-6. View abstract
  131. Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children. Journal Pediatrics. 1997; 130:898-905. View abstract
  132. Analysis of the maternal components of the AIDS clinical trials group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. Journal Infectious Disease. 1997; 175:971-4. View abstract
  133. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J. 1996 Dec; 15(12):1087-91. View abstract
  134. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1996 Dec; 174(6):1162-7. View abstract
  135. Secretory phospholipase A2 levels in rat small bowel. J Invest Surg. 1996 Jul-Aug; 9(4):313-9. View abstract
  136. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J. 1996 Mar; 15(3):247-54. View abstract
  137. Interferon gamma and IL-6 secretion of peripheral blood mononuclear cells is significantly increased in infants with perinatal HIV infection. 3rd National Human Retroviruses and Related Infections Conf. 1996; Washington DC. View abstract
  138. Functional characterization of autoreactive T-cells in acute disseminated encephalomyelitis. Pediatric Research. 1996; 40:548. View abstract
  139. Lack of correlation between CMV infection and central neurological compromise in HIV-infected children. 3rd National Human Retroviruses and Related Infections Conference. 1996; Washington DC. View abstract
  140. Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral apthhous ulcers. Pediatric Infectious Disease Journal. 1996; 15:465-7. View abstract
  141. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National institute of allergy and infectious diseases and infectious diseases collaborative antiviral study group. Journal Infectious Diseases. 1996; 174:1162-7. View abstract
  142. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatric Infectious Disease Journal. 1996; 15:247-54. View abstract
  143. Early Toxicity Experience in Combination Therapy of Advanced Pediatric HIV Disease. 35th ICAAC Conference. 1995; San Francisco. View abstract
  144. Clearance of HIV--lessons from newborns. N Engl J Med. 1995 Mar 30; 332(13):883-4. View abstract
  145. Clearance of HIV: Lessons from newborns. New England Journal Medicine. 1995; 332:883-4. View abstract
  146. Correlates of CNS Disease Progression in Children Vertically-Infected with HIV. 2nd National Human Retroviruses and Related Infections Conference. 1995; Washington DC. View abstract
  147. Defining Pediatric "Rapid HIV Progressors" by Plasma Viremia and Sequential Western Blot. 34th ICAAC Conference. 1994; Orlando. View abstract
  148. Protective Immunity. Perinatal and Pediatric Pathophysiology, A Clinical Perspective; Gluckman PB and Heymann MA, editors. 1993; 669-73. View abstract
  149. Maternal hepatitis C (HCV) infection is not a cofactor for enhanced rate of vertical transmission of HIV-I. 9th International Conference AIDS. 1993; Berlin. View abstract
  150. The Placental Barrier to HIV-1 Transmission. The AIDS Reader. 1993; Sept/Oct:163-5. View abstract
  151. Plasma viral load in symptom-free women and vertical transmission of HIV-1. Lancet. 1992 Dec 12; 340(8833):1470-1. View abstract
  152. Correlates of vertical transmission of human immunodeficiency virus (HIV). Inf Dis Soc for Obstet-Gynec. 1992. View abstract
  153. Maternal hepatitis C (HCV) infection does not enhance the rate of vertical transmission of HIV. 32nd ICAAC Conference. 1992; Anaheim. View abstract
  154. Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. J Clin Invest. 1992 Aug; 90(2):511-4. View abstract
  155. Early diagnosis of HIV in infants born to seropositive women. 8th International Conference on AIDS/STD World Congress. 1992; Amsterdam. View abstract
  156. Diminished interferon-gamma and lymphocyte proliferation in neonatal and postpartum primary herpes simplex virus infection. J Infect Dis. 1992 May; 165(5):813-8. View abstract
  157. The role of the placental macrophage in prevention of vertical transmission of HIV. Keystone Conference on Pediatric AIDS. 1992. View abstract
  158. Clostridium septicum infections in children. Pediatric Infectious Diseases Journal. 1992; 11:569-75. View abstract
  159. Culture: An early diagnostic tool in infants born to HIV infected women. 31st ICAAC Conference. 1991; Chicago. View abstract
  160. Diminished ability of fetal and neonatal macrophages to support proliferative human immunodeficiency infection. Clin Res. 1991; 39:382A. View abstract
  161. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991 May 02; 324(18):1247-52. View abstract
  162. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14; 324(7):450-4. View abstract
  163. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14; 324(7):444-9. View abstract
  164. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 1991 Feb; 163(2):226-32. View abstract
  165. Comparative susceptibility of neonatal lymphocytes and monocytes to HIV infection. 30th ICAAC. 1990; Atlanta. View abstract
  166. Modulation of in vitro monocyte cytokine responses to Leishmania donovani. Interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1. J Clin Invest. 1990 Jun; 85(6):1914-24. View abstract
  167. HIV infection in pregnancy and infancy in AIDS. Diagnosis and treatment. Handbook of AIDS Treatment, Holmes KK, Collier A, Corey L, Handsfield H, editors. 1990; 160-63. View abstract
  168. Modulation of in vitro monocyte cytokine responses during infection with Leishmania donovani. Interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1. Journal Clinical Investigation. 1990; 85:1914-24. View abstract
  169. Association between plasma human immunodeficiency virus type-1 (HIV) viremia and clinical class of pediatric HIV infection. 5th International Conference on AIDS. 1989; Montreal. View abstract
  170. The use of antiviral drugs in pregnancy for herpes simplex virus infections. Antiviral Chemotherapy, Mills J, Corey L, editors. 1989; 2:23-36. View abstract
  171. Production of lymphotoxin and tumor necrosis factor by human neonatal mononuclear cells. Pediatr Res. 1988 Dec; 24(6):717-22. View abstract
  172. Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. J Immunol. 1988 May 15; 140(10):3473-81. View abstract
  173. Enhanced production of monokines by canine alveolar macrophages in response to endotoxin-induced shock. . 1988 Apr; 187(4):408-15. View abstract
  174. Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes. Journal of Immunology. 1988; 140:3473-81. View abstract
  175. Enhanced production of monokines by canine alveolar macrophages in response to endotoxin-induced shock. Proceedings Society Experimental Biology Medicine. 1988; 187:408-15. View abstract
  176. Expression of HLA class II antigens and secretion of interleukin-1 by monocytes and macrophages from adults and neonates. Immunology. 1987 Jun; 61(2):195-201. View abstract
  177. The role of computerized tomographic scan in the management of Gradenigo's syndrome: a case report. Pediatr Infect Dis. 1984 Nov-Dec; 3(6):595-7. View abstract
  178. Immunologic profile of growth hormone deficient children before and during growth hormone replacement. Clin Res. 1984; 32(5):A895. View abstract